Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Gilteritinib Administered as Maintenance Thrpy Fllwng Allogeneic Transplant for Pts w/ FLT3/ITD AML

Protocol: BMT-CTN1506

Full Title

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

Leukemia Acute Myeloid Leukemia